The Effect of RECO-18 on Infertile Women Undergoing in Vitro Fertilization-embryo Transfer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-07-31

Study Completion Date

2023-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

How to improve the fertility of infertile women has become a hot topic in the field of assisted reproduction. Animal experiment has shown that RECO-18 significantly improved the female fertility in mice, and the specific mechanism was related to reducing follicular atresia, promoting follicle development and improving oocyte quality. Therefore the investigators aim to conduct a pilot study to explore the effect of RECO-18 in infertile women undergoing assisted reproduction treatment. This study is a prospective, randomized, controlled clinical study. The treatment group takes RECO-18 while the control group takes the multi-vitamins. The primary indicator is the ongoing pregnancy rate at 12 weeks' gestation; the secondary indicators are the number of oocytes retrieved, the normal fertilization rate and the rate of high quality embryos, implantation rate, clinical pregnancy rate, and early miscarriage rate.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Effect of Melatonin Supplementation on Cumulus Cells and IVF Outcomes

NCT06546774

Unrecognized Condition

RECRUITING NA

Effectiveness of Adjuvant Supplements Prior to in IVF

NCT05471453

Dietary Supplements

COMPLETED NA

Efficacy and Safety of Shen Que (RN8) Moxibustion in Unexpected POR

NCT05653557

Infertility

COMPLETED NA

To Investigate REKOVELLE in Chinese Women Undergoing Assisted Reproductive Technologies: Effectiveness, Safety, and Patterns of Use in Real-world Practice

NCT07029451

Infertility

RECRUITING

Antenatal Myo-inositol Supplementation in Pre-existing Diabetes

NCT07241221

Perinatal and Neonatal Outcomes in Pregnancies With Type 2 Diabetes Mellitus (T2DM)

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Mitochondrial function is closely related to oocyte quality in female. Deficiency of multiple micronutrients is common in infertile women, and supplementation with multiple micronutrients has antioxidant effects to reduce the damage of oxidative stress to fertility, and helps to improve the outcomes of assisted reproductive treatment. RECO-18 is a functional food containing a variety of plant extracts and enzymatic soy phospholipids. In in vivo and in vitro senescent models, the investigators found RECO-18 to improve oocyte quality mainly by regulating the mitochondrial apoptosis pathway. The investigators also found RECO-18 significantly improved the fertility of mice, and the specific mechanism was related to reducing follicular atresia, promoting follicle development and improving oocyte quality. Based on the animal experiments, the investigators intend to conduct a clinical trial to explore whether RECO-18 plays a role in improving oocyte and embryo quality and pregnancy outcomes in infertile women undergoing in vitro fertilization-embryo transfer.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Fertility Disorders Infertility, Female

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control group

The control group takes the multi-vitamins (Elevit, Bayer S.A.) with the dosage of one tablet per day on the 1st to 5th day of menstruation, then perform ovulation induction on the second menstrual cycle, and continue to take multi-vitamins until the day of oocyte retrieval.

Group Type ACTIVE_COMPARATOR

Multi-vitamins

Intervention Type DIETARY_SUPPLEMENT

one tablet daily, oral

Treatment group

The treatment group begins to take Reco-18 on the 1st to 5th day of menstruation with a dosage of 4 pills per day for the whole menstrual cycle, then perform ovulation induction on the second menstrual cycle, and continue to take Reco-18 until the day of oocyte retrieval.

Group Type EXPERIMENTAL

RECO-18

Intervention Type DIETARY_SUPPLEMENT

4 pills daily, oral

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

RECO-18

4 pills daily, oral

Intervention Type DIETARY_SUPPLEMENT

Multi-vitamins

one tablet daily, oral

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* female, 20 to 40 years old
* the 1st or 2nd cycle of IVF/ICSI treatment
* BMI≤30Kg/m2
* with bilateral ovaries
* be eligible for IVF/ICSI treatment

Exclusion Criteria

* Repeated implantation failures (with previous 3 or more IVF/ICSI failures)
* moderate to severe endometriosis
* untreated hydrosalpinx
* untreated endometrial disease
* contraindications for assisted reproductive techniques or gestation
* a history of ovarian surgery
* expected poor ovarian response (POR) or previous POR
* polycystic ovarian syndrome
* participants in clinical trials of other drugs within one month prior to enrollment; • hypersensitivity to follicle-stimulating hormone α, FSH, human menopausal gonadotropin, LH or excipients
* uncontrolled endocrine diseases (such as hyperthyroidism, hypothyroidism, adrenal gland disease, obesity, etc.)
* percutaneous epididymal sperm aspiration or testicular sperm aspiration

Minimum Eligible Age

20 Years

Maximum Eligible Age

40 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No